Tag: GTAEXS617

Exscientia begins enrollment for Phase 1/2 cancer trial of CDK7 inhibitor

businessnewstoday- July 11, 2023

AI-driven precision medicine company Exscientia has initiated enrollment for its Phase 1/2 "ELUCIDATE" study, marking the first trial of its precision-designed CDK7 inhibitor, GTAEXS617 ('617), ... Read More